Novartis Cosentyx Encouraging Results v Humira In Psoriatic Arthritis Trial

-- Cosentyx narrowly missed statistical significance for superiority in ACR 
      20, the primary endpoint of the EXCEED trial, while showing numerically 
      higher results versus Humira(R)*[1] 
 
   -- Statistically significant advantages of Cosentyx versus Humira(R)* in 
      psoriatic arthritis (PsA)-specific endpoints were observed in a 
      pre-specified sensitivity analysis[1] 
 
   -- EXCEED underscores Novartis commitment in rheumatology as first 
      double-blinded monotherapy head-to-head trial with a primary endpoint 
      specific to joints in PsA[1]

https://www.marketscreener.com/NOVARTIS-9364983/news/NOVARTIS-CHF0-50-REGD-Novartis-Cosentyx-R-Shows-Encouraging-Results-Versus-Humira-R-From-First-29496010/